CD34 and acute myeloid leukemia: The 28-patient subset on the right had a significantly lower age (Table S9; Fisher’s exact test, p = 0.00076), a lower frequency of undifferentiated FAB-M0/M1 leukemic cells (p = 0.0003), a lower frequency of CD34+ AML cell populations (p = 0.0307), higher frequencies of favorable (p = 0.0312) and favorable/normal karyotypes (p = 0.0299), a lower frequency of refractory/relapsed disease (p = 0.0365), and a higher frequency of long-term AML-free survival (p = 0.0016) compared with the 22-patient subset on the left.